Hematopoietic stem cells (HSC), with their dual ability for self-renewal and multilineage differentiation, constitute an essential component of hematopoietic transplants. Human fetal liver (FL) represents a promising alternative HSC source, and we reported simple culture conditions allowing long-term expansion of FL hematopoietic progenitors. In the present study, the NOD/SCID mouse xenotransplantation assay was used to confirm that human FL is rich in NOD/SCID-repopulating cells (SRC), and to show that these culture conditions repeatedly maintained short and long-term SRC from various FL samples for at least 28 days. Quantitative limited dilution analysis in NOD/SCID mice demonstrated for the first time that a 10 to over a 100 fold net expansion of FL SRC could be achieved after 28 days of culture. The efficiency of this culture system may lead to an increase in the use of FL as a source of HSC for transplantation in adult patients, as previously demonstrated with umbilical cord blood under different culture conditions.
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INTRODUCTION
There is a growing clinical need for large numbers of human hematopoietic stem cells (HSC) for transplantation or gene therapy 1, 2 . In cancer patients where the probability of tumor cell contamination in either leukapheresis or bone marrow (BM) is high, the use of allogeneic cells is preferable. Accumulated evidence suggests that fetal liver (FL) and/or umbilical cord blood (CB) represent alternative and possibly more "universal" sources of "early" HSC possessing a better proliferative potential and also a pre-immune status that may be important in mismatched transplant situations [3] [4] [5] [6] [7] . However, both sources are compromised by the relatively small number of cells available. Therefore, the future clinical potential of FL and CB would be strongly enhanced if methods allowing a reliable HSC expansion, perhaps to a degree as little as fold, without a loss of their engraftment ability, could be developed 8 . Ex-vivo expansion of CB and of adult NOD/SCID-repopulating cells (SRC, see 9 ) has been demonstrated (see for example 10, 11 ), but successful expansion of FL SRC has not been reported so far.
We recently published a simple and reproducible stroma-free liquid culture system allowing long-term (>6 months) expansion of human hematopoietic cells contained within previously frozen crude FL cell suspensions. In these cultures, CD34 + cells, primitive colony-forming progenitors, and cells possessing a putative stem cell phenotype were not only present, they also underwent a continuous amplification 12 . However, the maintenance and/or expansion of functional repopulating HSC was not tested. This is critical given the dissociation between stem cell phenotype and in vivo repopulating function observed in hematopoietic cultures [13] [14] [15] 
STUDY DESIGN
Cryopreserved human FL crude cellular suspensions were prepared from aborted fetuses (gestational weeks 12-17) as described, with the approval of the ethical committee of the Lausanne University Medical Faculty 12, 16 . Total nucleated FL hematopoietic cells were expanded in RPMI-1640 supplemented with 8% human AB plasma, Flt-3 ligand (50 ng/ml), interleukin-6 (10 ng/ml), megakaryocyte growth and development factor (MGDF, 10 ng/ml) and stem cell factor (SCF, 50 ng/ml). Cultures were fed and maintained as described 12 , except that cells were grown in T25 flasks instead of 24-well plates. For NOD/SCID repopulating assays, 6 to 8 week old NOD/LtSz-scid/scid (NOD/SCID) mice were sublethally irradiate d (375 cGy using a Cs-137 source), and cells to be tested (at the doses indicated, in ~600 µl RPMI) were injected into the lateral tail vein 4-24h later. Mice were killed after 6, 8 or 12 weeks, the BM harvested from femora, and human engraftment analyzed by flow cytometry using an anti-human CD45 antibody.
In most cases, multilineage engraftment was confirmed using a combination of antibodies as described 17 . For limited dilution analysis (LDA), a mouse was considered positive (engrafted) when low percentages of engraftment (<0.5% CD45 + cells) could be unequivocally confirmed by Southern blot hybridization 9, 17, 18 . Data from LDA experiments were analyzed by applying
Poisson statistics to the single-hit model, and the SRC frequency in each cell source calculated using the L-Calc software (StemCell Technologies, Vancouver, Canada).
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RESULTS AND DISCUSSION
Human HSC possessing in vivo repopulating capability can be functionally tested in the SRC assay 9 . We first determined whether FL SRC were maintained after 4 weeks in culture, when a large number of FL hematopoietic cells, potentially sufficient for transplantation into adult patients, could be harvested from a limited supply of unexpanded FL cells. Four different FL specimens were cultured for 28 days, and cohorts of 5 mice/sample were transplanted with 20×10 6 expanded viable total nucleated cells (TNC). Both short-and long-term SRC 19 were maintained in culture, as all mice analyzed contained large numbers of CD45 + human hematopoietic cells in their BM, whether tested ~6 or ~12 weeks after transplantation. A representative example of these analyses is shown in Fig. 1A . Overall, engraftment levels were higher at 12 weeks than at 6 weeks, demonstrating that expanded FL samples contained SRC capable of long-term repopulating potential. Additionally, the BM of all these mice contained cells committed to both lymphoid (positive for CD19, CD20) and myeloid lineages (CD14, CD15, CD33), as well as a significant fraction of putative primitive CD34 + /CD38 -hematopoietic progenitors. Interestingly, no significant differences in engraftment levels (total and/or lineagespecific) were observed if expansion was performed in 2 steps, i.e. freezing after 7 days of culture followed by three more weeks of culture, or if expanded cells were stored frozen before injection (data not shown). These results demonstrate that our culture conditions repeatedly maintained short and long-term FL SRC capable of in vivo lympho-myeloid differentiation for at least 28 days.
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In order to compare the maintenance and/or expansion of the FL repopulating stem cell compartment with that of other, more widely used HSC sources, we attempted to establish longterm hematopoietic cultures from CB and/or adult sources, under the same conditions we used for FL. With adult BM and/or mobilized peripheral blood, we never succeeded in obtaining longterm cultures that would last more than a few weeks, and after 28 days the number of cells generated was not sufficient for transplantation into NOD/SCID mice. With CB, we were only able to establish long-term cultures with about half of the samples tested, and the maintenance/expansion of SRC in NOD/SCID mice was not tested. However, these experiments cannot be compared with published reports of successful CB and/or adult SRC expansion (see for example 10, 11 Fig. 1B . In this FL specimen, the average SRC frequency was found to be 1 SRC in ~700'000 TNC, or ~1 in 50'000 hematopoietic CD45 + cells as this FL sample contained ~7% CD45 + cells (Table I) . Although not directly comparable, this frequency is much higher than those estimated in CB, adult BM or mobilized peripheral blood cells [9] [10] [11] , and it correlates well with the high SRC 20 . As could be expected, larger cell doses usually resulted in higher engraftment. However, the BM of mice transplanted with low cell numbers occasionally contained surprisingly high percentages of human CD45 + cells (e.g. Fig. 1B ). This could result from the large variability inherent to the NOD/SCID transplantation system 21 , and/or from the functional heterogeneity of the human HSC compartment, as demonstrated both in vitro and in vivo 22, 23 . Alternatively, this could also be stochastic, these mice having randomly received more SRC. Data from two additional FL samples are summarized in Table I , confirming that human FL is rich in SRC 24, 25 .
To analyze whether a net SRC expansion could be achieved, three FL specimens were expanded for 28 days and then analyzed in LDA experiments as above. For example, all mice transplanted with 1×10 6 expanded TNC from FL#841 ( Fig. 1C and D) , and the majority of mice injected with 0.5×10 6 cells (Fig. 1E) , were positively engrafted. Conversely, most mice transplanted with 0.25×10 6 expanded cells were not engrafted (Fig. 1E) . The calculated SRC frequency was found to be 1 in ~365'000 TNC or CD45 + cells, as the vast majority (>99%) of expanded cells in culture at 28 days were CD45-positive 12 . The total cellular expansion (fold increase in viable TNC) for this sample after 28 days of culture was ~24-fold, and the initial percentage of CD45 + cells was ~7.0% ( Table I ). Assuming that only CD45 + cells in unexpanded FL suspensions contributed to the massive hematopoietic cell amplification observed in culture, this represents a CD45 + cell expansion of ~343-fold; therefore, the net SRC expansion following 28 days of culture for this FL sample could be estimated to be ~46 fold. Data from two additional expanded FL samples are summarized in Table I . Although large differences in SRC frequencies were observed between FL specimens, both before and following culture, a 10-fold or more net SRC amplification was achieved in all cases.
For
The NOD/SCID transplantation system is extremely useful to test the repopulating potential of human hematopoietic cell populations, whether freshly isolated or after in vitro culture. However, it suffers from an important variability, both between but also within similar samples 21 , making it difficult to carefully assess the potential differences in engraftment of expanded vs unexpanded cells. Despite this variability, overall, no significant difference between the reconstitution capability of expanded vs unexpanded FL cells was observed in the present study. In other words, transplantation of equivalent numbers of expanded vs unexpanded FL SRC into NOD/SCID mice usually resulted in similar engraftment levels.
Together with our previous study 12 , the data presented here demonstrate for the first time that under appropriate conditions, human FL repopulating HSC could be expanded, allowing, in a period of ~4 weeks of culture, the in vitro generation of a sufficient number of FL hematopoietic stem, progenitor and mature cells to be used for transplantation in adults. Thus, as for CB, which is increasingly utilized for transplantation (reviewed in 8, 26 
